SCHEMBL31269092

SCHEMBL31269092

Cc1ccnc(Cn2c(-c3ccc(OCC(=O)N4CCC4)cc3Cl)nc3c(OC4(C)CC4)ncnc32)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ RAB9A P51151 3/20 0.40
▸ NPC1 O15118 3/20 0.40
▸ PIK3CD O00329 2/20 0.37
▸ ALDH1A1 P00352 4/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TP53 P04637 1/20 0.34
▸ TDP1 Q9NUW8 1/20 0.34
▸ CNR1 P21554 1/20 0.34
▸ HPGD P15428 3/20 0.34
▸ GAA P10253 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPK1 P28482 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ PDK2 Q15119 1/20 0.34
▸ LRRK2 Q5S007 2/20 0.33
▸ GHSR Q92847 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31269232 0.99 RAB9A (0.41) RAB9ANPC1PIK3CDALDH1A1KDM4E
SCHEMBL31269355 0.94 PIK3CD (0.38) RAB9ANPC1PIK3CDALDH1A1KDM4E
SCHEMBL31268921 0.94 FKBP1A (0.40) RAB9ANPC1PIK3CDALDH1A1KDM4E
SCHEMBL31268831 0.94 PIK3CD (0.38) RAB9ANPC1PIK3CDKDM4ESMN1; SMN2
SCHEMBL31269352 0.93 PIK3CD (0.37) RAB9ANPC1PIK3CDALDH1A1KDM4E
SCHEMBL31269447 0.92 PIK3CD (0.38) RAB9ANPC1PIK3CDALDH1A1KDM4E
SCHEMBL31269257 0.92 PIK3CD (0.36) RAB9ANPC1PIK3CDKMT2ASMN1; SMN2
SCHEMBL31269207 0.91 PIK3CD (0.38) RAB9ANPC1PIK3CDKMT2ASMN1; SMN2
SCHEMBL31269075 0.91 PIK3CD (0.35) RAB9ANPC1PIK3CDKMT2ASMN1; SMN2
SCHEMBL31268819 0.90 PIK3CD (0.36) PIK3CD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4689155-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS Astrazeneca AB (SE) 2026-02-11 — — EP disclosed
WO-2024201368-A1 USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS ASTRAZENECA AB (SE) 2024-10-03 — — WO disclosed
Send feedback